BioCentury | Oct 29, 2012
Emerging Company Profile

Regenesance: Stopping the MAC attack

Regenesance B.V. is developing mAbs against complement 6 that may halt nerve damage and provide a better safety profile than standard of care for the orphan neurological disease myasthenia gravis. The mAbs are in lead...
BioCentury | Aug 27, 2001

Ebb & Flow

Most of the private companies that raised money in the first half of 2000 - when the genomics "revolution" was driving super-high octane valuations - bought about a year-and-a-half of cash, which would put them in money-raising...
BC Week In Review | Aug 15, 1994
Company News

Calgene other research news

The Davis, Calif., company announced expression in canola plants of a gene for producing high levels of 8- and 10-carbon medium-chain fatty acids. The Cuph-2 gene was taken from a wild plant, Cuphea hookeriana, which...
Items per page:
1 - 3 of 3